Date: 04/24/2020

RE: Discontinuation of Sale and Distribution of Coumadin® (Warfarin Sodium) Tablets, for oral use.

Dear Sir/Madam,

Bristol-Myers Squibb would like to inform you that the sale and distribution of all strengths of Coumadin® (Warfarin Sodium) tablets will be discontinued in the United States, Canada, Latin America, and Saudi Arabia, due to an unexpected, manufacturing issue. This action is voluntary and is not the result of any quality, safety or efficacy issues regarding the product, but rather due to an unexpected manufacturing issue that cannot be resolved. The discontinuation of this product in the U.S.A. happened on April 24th, 2020.

Indication:

COUMADIN is a vitamin K antagonist indicated in:

- Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism
- Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement
- Reduction in the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.

For patients currently using Coumadin® (warfarin Sodium) tablets, health care providers will be required to consider alternatives. BMS cannot recommend a specific product. Prescribing an alternative product is the clinical decision of the health care professional in consultation with the patient.

Please ensure this information is shared as appropriate with your target audiences.

If you have questions or require additional information regarding the discontinuation of Coumadin® Tablets, please contact our Medical Information Department at http://www.globalbmsmedinfo.com.

Sincerely,

[Signature]

Ricardo Garcia-Sanchez, MD
Group Director | U.S. Medical
Cardiovascular & Mature Brands